# Safety and Efficacy of Ranibizumab in Diabetic Macular Edema

> **NCT01131585** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 128 (actual)

## Conditions studied

- Visual Impairment Due to Diabetic Macular Edema

## Interventions

- **PROCEDURE:** Active laser photocoagulation
- **DRUG:** Sham injections
- **DRUG:** Ranibizumab 0.5 mg

## Key facts

- **NCT ID:** NCT01131585
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 128 (ACTUAL)
- **Why stopped:** European drug approval.
- **Last updated:** 2012-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01131585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01131585, "Safety and Efficacy of Ranibizumab in Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT01131585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*